Ally Bridge Group (ABG), a cross-border life science investment group, has completed a Series A investment, as the first part of a total of US$50 million raise, in Quantum Surgical, an innovative surgical robotics company in France.
Quantum Surgical is developing next-generation robotic solutions for minimally invasive cancer therapies. Quantum’s predecessor company Medtech SA, a leading French neurosurgical robotics company, was acquired by global orthopaedics giant Zimmer Biomet in 2016 after an investment from ABG in 2015.
“ABG is excited to support again the Quantum Surgical team led by Bertin Nahum in their new venture following our successful investment in—and exit from—Medtech SA. The team has been dedicated to—and has a proven track record—in developing and commercialising innovative surgical robots globally. ABG has been working closely with Quantum Surgical since its inception and our partnership now breaks into new ground in building next-generation surgical robots to facilitate interventional oncology treatment, especially for early-stage cancer patients,” says Frank Yu, Founder, CEO and CIO of Ally Bridge Group. “Quantum Surgical is a natural extension of ABG’s recently led US$300 million investment in GRAIL, a healthcare company whose mission is to detect cancer early, when it can be cured. Early cancer detection must be accompanied by more effective early treatment,” Frank Yu adds.
“Quantum will set new standards for minimally invasive cancer treatment procedures. We are excited to partner up with Ally Bridge Group again, after our successful collaboration in 2015-2016, and to continue to benefit from ABG’s truly global industry perspectives, network and strong financing, capital markets and M&A capabilities,” says Bertin Nahum, Founder and CEO of Quantum Surgical.
Lifetech Scientific, a leading innovative medtech company in China, has also participated in the investment through its joint venture with ABG and will collaborate with Quantum Surgical in China market.
